NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has again said no to recommending GSK's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab) for treating metastatic hormone-receptor-positive breast cancer that overexpresses HER2. Roche is thinking of appealing, while GSK is "considering its options", the companies told Scrip.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.